机构：[1]Royal National ENT Hospital and University College, London, United Kingdom[2]Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, no. 2, Ciudad Universitaria de Cantoblanco, Madrid, Spain[3]Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium[4]Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium[5]Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark[6]Medical College of Georgia at Augusta University, Augusta, GA, United States[7]Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden[8]Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden[9]Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore[10]Division of Allergy & Immunology, Department of Medicine, Queen’s University, Kingston, ON, Canada[11]Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, Netherlands[12]Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London, United Kingdom[13]Patient Advisory Board, European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium[14]Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark[15]Laboratory of Upper Airways Research, Department of Otorhinolaryngology, University of Ghent, Ghent, Belgium[16]Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium[17]Department of Otorhinolaryngology, Cliniques Universitaires Saint Luc, Brussels, Belgium[18]Department of Otorhinolaryngology/Head and Neck Surgery, University Hospital Centre “Sestre milosrdnice”, Zagreb School of Medicine, Zagreb, Croatia[19]Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany[20]Allergy Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom[21]The Allergy Clinic, Johannesburg, South Africa[22]ClinCompetence Cologne GmbH, Cologne, Germany[23]Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany[24]Rhinology Unit & Smell Clínic, Department of Otorhinolaryngology, Hospital Clínic Barcelona, Universitat de Barcelona, FRCB-IDIBAPS, CIBERES, Barcelona, Catalonia, Spain[25]Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom[26]Department of Pediatrics, Nippon Medical School, Bunkyo-ku, Tokyo, Japan[27]Observational and Pragmatic Research Institute, Singapore, Singapore[28]Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom[29]Usher Institute, University of Edinburgh, Edinburgh, Scotland[30]Allergy Department, Royal Brompton Hospital, London, United Kingdom[31]Griffth University, Southport, QLD, Australia[32]Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom[33]Charite University Medicine, Berlin, Germany[34]Department of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China临床科室耳鼻咽喉-头颈外科变态反应科首都医科大学附属北京同仁医院首都医科大学附属同仁医院
Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the light of new knowledge and treatment options, there is a necessity to update or revise fundamental AR definitions to facilitate communication across diverse specialties engaged in its treatment and to improve patient care. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) convened a meeting of experts and patient representatives to deliberate the optimal methodology for measuring AR treatment responses and establishing novel treatment goals. This paper presents a consensus on revised AR definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory severe allergic rhinoconjunctivitis (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat to target, relapse, progression, disease modification, and prevention.
第一作者机构：[1]Royal National ENT Hospital and University College, London, United Kingdom
通讯作者：
推荐引用方式(GB/T 7714)：
Scadding G. K.,Conti D. M.,Scheire S.,et al.EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR[J].FRONTIERS IN ALLERGY.2025,5:doi:10.3389/falgy.2024.1531788.
APA：
Scadding, G. K.,Conti, D. M.,Scheire, S.,Backer, V.,Blaiss, M....&Gevaert, P..(2025).EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR.FRONTIERS IN ALLERGY,5,
MLA：
Scadding, G. K.,et al."EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR".FRONTIERS IN ALLERGY 5.(2025)
